Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-P115C in advanced PRAME-positive cancers
NCT07156136Phase 1Recruiting
- Sponsor
- Immunocore
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 1, open-label trial of IMC-P115C in solid tumor, sponsored by Immunocore. Primary endpoints: Percentage of participants with dose-limiting toxicities at 16 months, Percentage of participants with adverse events at 16 months and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
IMC-P115C
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07156136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156136.